Over-Prescription of the Imidazoline Receptor Agonists: Evidence for Restriction of the Therapeutic Indication-Reference-Cited by-同舟云学术

Over-Prescription of the Imidazoline Receptor Agonists: Evidence for Restriction of the Therapeutic Indication

Published:2022-07-30 Issue:5 Volume:56 Page:859-866
ISSN:2168-4790
Container-title:Therapeutic Innovation & Regulatory Science
language:en
Short-container-title:Ther Innov Regul Sci

Author:

Jankūnas Rimas^ORCID,Rinkūnienė Diana,Stakišaitis Donatas

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Link

https://link.springer.com/content/pdf/10.1007/s43441-022-00434-9.pdf

Reference36 articles.

1. Yusuf PS, Hawken S, Ôunpuu et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case–control study. Lancet. 2004;364:937–52. https://doi.org/10.1016/S0140-6736(04)17018-9.

2. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med. 1993;153:598–615. https://doi.org/10.1001/archinte.153.5.598.

3. Our World in Data. https://ourworldindata.org/grapher/cardiovascular-disease-death-rates?time=2017®ion=Europe. Accessed Feb 13 2021.

4. Causes of death statistics - Statistics Explained. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Causes_of_death_statistics#Causes_of_death_in_EU_Member_States_in_2016. Accessed Feb 13 2021.

5. World Health Organization. The Pursuit of Responsible Use of Medicines. https://apps.who.int/iris/bitstream/handle/10665/75828/WHO_EMP_MAR_2012.3_eng.pdf?sequence=1&isAllowed=y. Accessed June 17 2021.